Summary To estimate the prevalence of TP53 mutations in familial breast cancer, constant denaturant gel electrophoresis (CDGE) was used to screen exons 5-8 of the TP53 gene for germline mutations. Genomic DNA from 128 breast cancer patients belonging to 109 families with familial cancer were screened. No germline mutations were found in any of the patients. We also studied TP53 mutations in tumour DNA from 51 of the same individuals and found mutations in 14%. This is similar to what has been reported in sporadic breast cancer.
The p53 protein is a transcription factor and is frequently altered by mutation in most types of cancer. The majority of the mutations are missense mutations (Hollstein et al, 1994) .
Germline mutations in the TP53 gene were found to segregate in families with the Li-Fraumeni syndrome resulting in a very high risk for early onset breast cancer, sarcoma, leukaemia, brain tumours and other tumours (Malkin, 1994; Wang et al, 1995) . It has also been shown that not all families with the classical criteria for Li-Fraumeni segregate a mutation in p53, while some other families with non-classical Li-Fraumeni syndrome do (Birch et al, 1994) . Germline mutations have also been found in families with breast and ovarian cancer (Prosser et al, 1992; Jolly et al, 1994) . However, germline mutations have not been found to segregate frequently in breast cancer families or patients with early onset or bilateral disease (Prosser et al, 1991; Sidransky et al, 1992; B0rresen et al, 1992; Lidereau and Soussi, 1992) .
One study, which compared the frequency of somatic TP53 mutations in sporadic breast carcinomas with tumours from patients with a family history, showed that, while sporadic TP53 mutations occurred in 13% of the sporadic tumours, the frequency in the familial cases was 58% (Glebov et al, 1994) .
We have used constant denaturant gel electrophoresis (CDGE) to screen for germline mutations in exons 5-8 of the TP53 gene in members from 109 breast cancer families. This study also involved searching for mutations in 51 of the tumours from our patients with familial breast cancer.
MATERIALS AND METHODS Patients
A total of 128 patients from 109 families with familial cancer, predominantly breast cancer, were identified. The families were selected as described (Lindblom et al, 1992a Correspondence to: A Lindblom number of breast cancer and other cancer diagnoses, the families were categorized as follows: 45 families were defined as breast cancer families and 25 families were defined as cancer families using the following criteria. Breast cancer family -at least three first-or second-degree relatives with breast cancer. Cancer family -the index patient with breast cancer plus at least three first-or second-degree relatives with cancer. The remaining 39 families had a family history of two first-degree relatives with breast cancer. Tumour tissue was available from 51 of these patients.
Loss of heterozygosity (LOH)
Blood and tumour samples from the patients were obtained. All tumours had been surgically removed before radiation or chemotherapy and fresh specimens were frozen at -70°C, and stored for periods varying from 6 months to 12 years before DNA isolation. Constitutional and tumour genotypes were compared by using restriction fragment length polymorphism (RFLP) analysis: D17S5/YNZ22.1 with RsaI on the distal part of 17p; D17S31/MCT35 with MspI at the TP53 locus. A polymerase chain reaction (PCR)-based intragenic p53 marker involving a CA repeat polymorphism (Ishimaru et al, 1994) was also used to study LOH. Allelic loss was detected as either a total absence or a reduced signal intensity (<50%) of one of the constitutional alleles as scored by the naked eye. When necessary this was confirmed by densitometry. Tumours were analysed with respect to the number of normal cells compared with malignant cells on representative slides. These estimates were coded by an independent pathologist.
All the conditions and PCR primers (shown in Figure 1 ) for CDGE have been described previously (B0rresen et al, 1991; Smith-S0rensen et al, 1993; Andersen et al, 1995) . A specific analysis was made to identify a frequently described G to C mutation in codon 156. The exon 5 was amplified using the same primers (covering codon 126-160, Figure 1) gel electrophoresis (Figure 2) , and the wild-type and mutant codon 156 could be distinguished.
Sequencing
Exon 5 was divided into two overlapping fragments for sequencing ( Figure 1 and Table 1 ). For both exons 6 and 7, one pair of primers was used for the PCR and an internal primer was used to sequence the PCR product ( Figure 1 and Table 1 ). In all cases, genomic DNA was used as the template to amplify the fragment with the PCR primers. Rapid PCR sequencing method (Murray, 1989) 
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had a missense mutation in codon 173, GTG-4TTG and A common mutation in codon 156 in exon 5 is not detected by GTG-~CTG, leading to the same amino acid change (valine to CDGE using the conditions described. Therefore, a specifi'c test leucine). Two tumours showed a C-*T change in codon 213 in using restriction analysis with BstUI enzyme was performed to exon 6 resulting in a stop codon. In exon 7, we found two missense screen for this particular mutation (Figure 2 ). No mutation was mutations, one in codon 238 (T-*A), which changes a cysteine to found.
British Journal of Cancer (1997) We also analysed all tumours for LOH using three markers. One of these, D17S5, is located distally on chromosome 17p. This marker has frequently been used in LOH studies in breast cancer. Another marker, D17S3 1, is located close to the TP53 gene and a third one is intragenic. The results from the first two markers have been published previously (Lindblom et al, 1992b) . The overall result showed LOH distal on 17p, D17S5 region, in 22% of the tumours. Using the intragenic p53 marker, eight of 35 informative tumours showed LOH (23%) and when both D17S31 and the intragenic p53 marker were used, 33% of the tumours displayed LOH in the p53 region. The tumours with p53 mutations and their LOH data are shown in Table 2 .
DISCUSSION
Some studies have suggested that the tumour-suppressor gene, TP53, is involved in approximately 1% of familial breast cancer cases (Prosser et al, 1991; Sidransky et al, 1992; B0rresen et al, 1992; Lidereau and Soussi, 1992) . We studied patients from 109 breast cancer families and found no germline mutation in p53, confirming this low frequency. This means that there is little or no clinical benefit in screening patients from families with a history of primary breast cancer for germline mutations in p53. Only a few of our families have germline mutations in the BRCAJ (Miki et al, 1994 ) and BRCA2 (Wooster et al, 1995) genes (unpublished results). Therefore, it is possible that in most of these families other breast cancer susceptibility genes may be segregating, increasing the overall risk. These genes are still to be identified.
The frequency of somatic mutations in these familial tumours is not different from that of sporadic breast tumours, whereas the rate of mutations is between 15% and 25%. The specific G to C mutation in codon 156 of the TP53 gene that was found in 44% of the tumours from familial cases in a previous study (Glebov et al, 1994) is not seen in this cohort of patients. In a cohort of 88 Norwegian familial breast cancer cases, this mutation was found in the tumours from two cases (unpublished results). These results suggest that this particular mutation is not a main hotspot for mutation in familial breast cancer cases, nor does this reflect a difference between populations.
